Pacira Biosciences (PCRX) closed at $36.46 on November 13, 2026, unchanged from the previous close, on volume of 1,925,508 shares (30-day average 2,103,192).
Data as of November 13, 2026.
13-Nov-2026
Pacira Faces Partial Reversal in EXPAREL Royalty Dispute
TipRanks (Thu, 12-Nov 5:22 PM ET)
Ingram Micro to join S&P SmallCap 600, replacing Pacira BioSciences
Seeking Alpha News (Thu, 12-Nov 4:34 AM ET)
Ingram Micro set to join S&P SmallCap 600 following Viatris-Pacira deal
Seeking Alpha News (Thu, 12-Nov 12:47 AM ET)
Ingram Micro Holding Set to Join S&P SmallCap 600
PRNewswire (Wed, 11-Nov 6:51 PM ET)
Are BWIN, CCC, PCRX Obtaining Fair Deals for their Shareholders?
PRNewswire (Wed, 11-Nov 1:43 PM ET)
Business Wire (Thu, 5-Nov 5:01 PM ET)
Viatris Reports Third-Quarter 2026 Financial Results
PRNewswire (Thu, 5-Nov 6:59 AM ET)
Globe Newswire (Wed, 4-Nov 8:55 AM ET)
Are BWIN, LFCR, PCRX Obtaining Fair Deals for their Shareholders?
PRNewswire (Tue, 3-Nov 7:09 PM ET)
PRNewswire (Tue, 3-Nov 12:19 PM ET)
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Pacira Biosciences trades on the NASDAQ stock market under the symbol PCRX.
As of November 13, 2026, PCRX stock price was flat at $36.46 with 1,925,508 million shares trading.
PCRX has a beta of -0.00, meaning it tends to be less sensitive to market movements. PCRX has a correlation of 0.00 to the broad based SPY ETF.
PCRX has a market cap of $1.46 billion. This is considered a Small Cap stock.
Last quarter Pacira Biosciences reported $177 million in Revenue and $.70 earnings per share. This fell short of revenue expectation by $-6 million and exceeded earnings estimates by $.02.
In the last 3 years, PCRX traded as high as $36.67 and as low as $11.16.
The top ETF exchange traded funds that PCRX belongs to (by Net Assets): IJR, IWM, AVUV, VTI, VB.
PCRX has outperformed the market in the last year with a price return of +54.4% while the SPY ETF gained +13.4%. PCRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +57.3% and +0.2%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
PCRX support price is $36.42 and resistance is $36.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PCRX shares will trade within this expected range on the day.
